Propofol: Difference between revisions
(→Special Populations: added) |
|||
| (11 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: [[Sedative agent]] | *Type: [[Sedative agent]] | ||
*Dosage Forms: | *Dosage Forms: 10mg/mL | ||
*Common Trade Names: Diprivan | *Common Trade Names: Diprivan | ||
==Adult Dosing== | ==Adult Dosing== | ||
===Standard Induction Sedation=== | ===Standard Induction Sedation=== | ||
*Induction = 0.5- | *Induction = 0.5-1 mg/kg IV over 10s, followed by 0.5 mg/kg every 2-3 minutes as needed | ||
*Small incremental doses (10- | *Small incremental doses (10-30 mg) can slowly be administered to effect conscious sedation | ||
===Other=== | ===Other=== | ||
*Maintenance dose for sedation between 0.1-0.2/kg/min or 25- | *Maintenance dose for sedation between 0.1-0.2 mg/kg/min or 25-50 mg IV PRN in healthy patients < 55 years of age | ||
*Antiemetic dosing, 10- | *Antiemetic dosing, 10-20 mg IV or 10 μg/kg/min infusion | ||
===Adjunctive medications=== | ===Adjunctive medications=== | ||
| Line 21: | Line 21: | ||
*5-50 mcg/kg/min IV, increase 5 mcg/kg/min q10min | *5-50 mcg/kg/min IV, increase 5 mcg/kg/min q10min | ||
*Avoid prolonged use, especially of high doses, to avoid propofol infusion syndrome (PRIS) | *Avoid prolonged use, especially of high doses, to avoid propofol infusion syndrome (PRIS) | ||
*PRIS usually associated with >65 mcg/kg/min for >24hrs, and critically ill patients with increased endogenous glucocorticoids and catecholamines | *[[PRIS]] usually associated with >65 mcg/kg/min for >24hrs, and critically ill patients with increased endogenous glucocorticoids and catecholamines | ||
**PRIS: Heart failure, [[Rhabdomyolysis]], metabolic acidosis, renal failure | **[[PRIS]]: [[Heart failure]], [[Rhabdomyolysis]], [[metabolic acidosis]], renal failure | ||
*Propofol drip of these high dosages can be seen in post-intubation status epilepticus (drip 2-10mg/kg/hr) | *Propofol drip of these high dosages can be seen in post-intubation [[status epilepticus]] (drip 2-10mg/kg/hr) | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Induction (3-16 yo) at 2.5-3. | *Induction (3-16 yo) at 2.5-3.5 mg/kg IV | ||
*[[Procedural sedation]] | *[[Procedural sedation]] 1 mg/kg (max 40 mg), then 0.5 mg/kg PRN (max 20 mg) | ||
*Pediatric population especially at risk for [[Propofol infusion syndrome|propofol infusion syndrome (PRIS)]] | |||
==Special Populations== | ==Special Populations== | ||
| Line 65: | Line 66: | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 40 minutes (initial); 24-72 hr (after 10-day infusion) | ||
*Metabolism: Hepatic | *Metabolism: Hepatic | ||
*Excretion: Renal | *Excretion: Renal | ||
| Line 80: | Line 81: | ||
*[[Sedation (Main)]] | *[[Sedation (Main)]] | ||
*[[Ketofol]] | *[[Ketofol]] | ||
*[[Propofol infusion syndrome]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Critical Care]] | |||
Latest revision as of 14:20, 5 December 2023
General
- Type: Sedative agent
- Dosage Forms: 10mg/mL
- Common Trade Names: Diprivan
Adult Dosing
Standard Induction Sedation
- Induction = 0.5-1 mg/kg IV over 10s, followed by 0.5 mg/kg every 2-3 minutes as needed
- Small incremental doses (10-30 mg) can slowly be administered to effect conscious sedation
Other
- Maintenance dose for sedation between 0.1-0.2 mg/kg/min or 25-50 mg IV PRN in healthy patients < 55 years of age
- Antiemetic dosing, 10-20 mg IV or 10 μg/kg/min infusion
Adjunctive medications
- Fentanyl or morphine (propofol does not provide analgesia)
- NS for transient hypotension
- Lidocaine flush (to reduce injection pain)
ICU Sedation
- 5-50 mcg/kg/min IV, increase 5 mcg/kg/min q10min
- Avoid prolonged use, especially of high doses, to avoid propofol infusion syndrome (PRIS)
- PRIS usually associated with >65 mcg/kg/min for >24hrs, and critically ill patients with increased endogenous glucocorticoids and catecholamines
- PRIS: Heart failure, Rhabdomyolysis, metabolic acidosis, renal failure
- Propofol drip of these high dosages can be seen in post-intubation status epilepticus (drip 2-10mg/kg/hr)
Pediatric Dosing
- Induction (3-16 yo) at 2.5-3.5 mg/kg IV
- Procedural sedation 1 mg/kg (max 40 mg), then 0.5 mg/kg PRN (max 20 mg)
- Pediatric population especially at risk for propofol infusion syndrome (PRIS)
Special Populations
- Pregnancy Rating: Drug of choice for induction in pregnancy (only Category B induction agent)
- Lactation risk:
- Renal Dosing
- Adult
- No adjustment necessary
- Pediatric
- No adjustment necessary
- Adult
- Hepatic Dosing
- Adult
- No adjustment necessary
- Pediatric
- No adjustment necessary
- Adult
Contraindications
- Allergy to class/drug
- Allergy to soy or eggs
- Hypotension
- Aortic stenosis
Higher Risk
- Patients >55 years old
- Debilitated patients
- Patients with significant underlying illness (i.e. ASA physical status score III or IV)
- Optimize volume status before administration
- Largest decrease in systemic BP (vasodilation with only small increase in HR) compared with other induction drugs
Adverse Reactions
- Respiratory depression
- Transient hypotension
- Pain at injection site (inject lidocaine 20-40mg IV and fentanyl 50 mcg IV first)
- Hypertriglyceridemia - check TG levels in ICU setting
- Cardiac arrest (patients with significant cardiac disease receiving propofol for induction at highest risk)
- Propofol infusion syndrome (PRIS)
Pharmacology
- Half-life: 40 minutes (initial); 24-72 hr (after 10-day infusion)
- Metabolism: Hepatic
- Excretion: Renal
- Mechanism of Action: GABA agonist
- Rapid onset (90-100 seconds) and short duration (2-8 minute)
- Wake up after induction dose usually 8-10 min
Comments
- Seizure-like activity possible during induction, but safe in seizure disorder (most studies actually support anticonvulsant effect)
- Has significant anti-emetic activity
- Associated with static or reduced intracranial pressure in head injured patients requiring ICU Sedation[1]
See Also
References
- ↑ McKeage, K. and Perry, C. M. (2003) ‘Propofol’, CNS Drugs, 17(4), pp. 235–272.
